ClinicalTrials.gov
public full text
Public Domain
CP-751,871 Treatment For Patients With Multiple Myeloma
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma#892650
- Study of ABT-751 in Patients With Refractory Hematologic Malignancies#899636
- Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy#807312
- Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients#871623
- Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma#366600
Record · ID 837053
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive